An official website of the United States government
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Trial Status: active
This is a Phase III trial where participants will be randomized to two treatment groups,
which means participants will be assigned by equal chance to a treatment group. This
trial will be double-blinded, which means neither the participants nor the trial doctors
will know which of the two treatments the participants actually receive. Participants
will receive either the trial drug with chemotherapy or placebo (which looks like the
trial drug but does not have any drug in it) with chemotherapy.
Inclusion Criteria
Are considered ineligible for combination treatment with a monospecific PD(L)1 targeting immunotherapy plus chemotherapy as per their tumor PD-L1 expression status.
Have confirmed locally recurrent inoperable or metastatic TNBC, or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER and/or progesterone receptor [PgR]) 1% to 10%, HER2 immunohistochemistry [IHC] 0, 1+, or 2+ with fluorescence in situ hybridization [FISH] negative for HER2 gene amplification) documented prior to trial screening as part of standard of care.
Have at least one measurable lesion as the targeted lesion based on RECIST v1.1.
Have provided a tissue sample, archival or fresh, during the screening period (bone biopsies, fine needle aspiration biopsies, and samples from pleural or peritoneal fluid are not acceptable; participants with only one target lesion are not eligible to participate in the trial).
Eastern cooperative oncology group (ECOG) performance status of 0 or 1.
Exclusion Criteria
Have received any of the following therapies or drugs prior to the initiation of trial:
Have received prior systemic anticancer therapy for advanced disease.
Have received prior treatment with a PD(L)-1/vascular endothelial growth factor (VEGF) bispecific antibody.
Have received systemic corticosteroids (at a dosage greater than 10 milligrams [mg]/day of prednisone or an equivalent dose of other corticosteroids) within 7 days prior to the initiation of trial treatment. Exception: excluding local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (<= 7 days) of corticosteroids for prophylaxis (for example, prevention of contrast agent allergy) or treatment of non-autoimmune conditions (for example, delayed hypersensitivity reactions caused by exposure to allergens).
Have been vaccinated with live attenuated vaccine(s) within 4 weeks prior to initiation of trial treatment.
Have received broad-spectrum intravenous antibiotics therapy within 2 weeks prior to initiation of trial treatment.
Are pregnant or breastfeeding or are planning pregnancy or planning to father children during the trial or within 6 months after the last dose of pumitamig or placebo.
Have undergone major organ surgery, significant trauma, or invasive dental procedures (such as dental implants) within 28 days prior to the initiation of trial treatment or plan to undergo elective surgery during the trial. Placement of vascular infusion devices is allowed.
Have received allogeneic hematopoietic stem cell transplantation or organ transplantation.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07173751.
Locations matching your search criteria
United States
California
Palo Alto
Stanford Cancer Institute Palo Alto
Status: Active
Name Not Available
Michigan
Detroit
Wayne State University/Karmanos Cancer Institute
Status: Approved
Name Not Available
The study consists of a:
1. Screening period (up to 28 days);
2. Treatment period, during which participants will receive pumitamig or placebo in
combination with chemotherapy (until disease progression, the occurrence of
intolerable toxicity, withdrawal, death, or trial termination [whichever comes
first]);
3. Safety follow-up (FU) period (for up to 90 days after administration of the last
dose of trial treatment) and survival follow-up (until the participant dies,
withdraws consent for survival status follow-up, loss of contact, or sponsor
decision, whichever occurs first).
Participants will be randomized 1:1 to receive either pumitamig in combination with the
treatment of physician's choice (TPC) chemotherapy (Arm 1) or placebo in combination with
TPC chemotherapy (Arm 2). Chemotherapy will be administered per standard of care. The
randomization will be stratified based on the following factors:
- Prior treatment with cancer immunotherapy (yes versus no)
- On-trial chemotherapy regimen (paclitaxel/nab-paclitaxel versus gemcitabine plus
carboplatin versus eribulin)
- Geography (East Asia versus the rest of the world [ROW])
- PD-L1 status (combined positive score [CPS] less than [<] 1 versus 1 less than or
